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Abstract
In breast and colon cancers, transforming growth
factor (TGF)-B signaling initially has an antineoplastic
effect, inhibiting tumor growth, but eventually exerts
a proneoplastic effect, increasing motility and cancer
spread. In prostate cancer, studies using human
samples have correlated the loss of the TGF-B type
II receptor (TBRII) with higher tumor grade. To
determine the effect of an inhibited TGF-B pathway
on prostate cancer, we bred transgenic mice express-
ing the tumorigenic SV40 large T antigen in the
prostate with transgenic mice expressing a dominant
negative TBRII mutant (DNIIR) in the prostate. Trans-
gene(s) and TGF-B1 expression were identified in the
prostate and decreased protein levels of plasminogen
activator inhibitor type I, as a marker for TGF-B
signaling, correlated with expression of the DNIIR.
Although the sizes of the neoplastic prostates were
not enlarged, increased amounts of metastasis were
observed in mice expressing both transgenes com-
pared to age-matched control mice expressing only
the large T antigen transgene. Our study demon-
strates for the first time that a disruption of TGF-B
signaling in prostate cancer plays a causal role in
promoting tumor metastasis.
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Introduction
Prostate cancer is a heterogeneous disease that typically
progresses from prostatic intraepithelial neoplasia (PIN) to
locally invasive to potentially metastatic carcinoma. Surgi-
cal treatment of locally invasive cancer yields a 10-year
progression-free survival probability of greater than 90%. In
contrast, the development of metastatic cancer drops the
survival probability to about 30% [1]. Metastasis occurs in
late-stage prostate cancer wherein some cancers with the
loss of p53,RB, and the TGF-h type II receptor (ThRII) have
been identified [2–5]. The ThRII transduces signal for the
ubiquitous, pleiotropic cytokine transforming growth factor
(TGF)-h that is involved in many pathways including growth
inhibition, apoptosis, and differentiation [6–8]. TGF-h signaling
involves the binding of ligand to the extracellular domain of
ThRII, the transphosphorylation of the TGF-h type I receptor by
the cytoplasmic domain of ThRII, and the subsequent phos-
phorylation of Smad signaling molecules that can activate the
transcription of downstream targets such as plasminogen
activator inhibitor type I (PAI-I) [9,10]. Although the loss of
the ThRII has been associated with prostate cancer, its effect
on tumor progression has not been determined. We have
studied transgenic mouse models of prostate cancer to exam-
ine the effect of blocking the TGF-h signaling pathway on tumor
development and progression.
The large probasin (LPB) promoter directed the prostatic
epithelial cell expression of the SV40 large T antigen (Tag) [11],
with a deletion in the early region to remove the small t antigen.
The oncogenic Tag has been reported to induce neoplasia by
sequestering and inactivating two tumor suppressor genes,
p53 and RB, that have been associated with prostate cancer
[2,3]. Two LPB-Tag lines, 12T-7f and 12T-10, were used to
study different aspects of prostate tumor progression. The 12T-
7f line developed prostate tumors of lethal size by 23 weeks
of age that contained high-grade prostatic intraepithelial
neoplasia (HGPIN) and occasional foci of invasive carcinoma
(IC) [12]. We chose this line to test whether blocking TGF-h
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signaling would promote progression from cancer precursors
to more locally invasive and/or metastatic cancer. However,
the 12T-10 line developed small prostate lesions containing
HGPIN and invasive neuroendocrine carcinoma that became
metastatic after 6 months of age [13]. This line was selected
to determine whether inhibiting the TGF-h pathway would
modify the metastatic phenotype.
Although multiple lines were made with the probasin
promoter to target the dominant negative ThRII mutant
(DNIIR) in the prostate of transgenic mice, none of the lines
expressed the DNIIR transgene (unpublished observation).
The zinc-inducible metallothionein (MT) promoter was well
suited to express the transgene in the prostate because the
prostate contains naturally high levels of zinc and expresses
several MTs in the epithelium [14]. The DNIIR construct had
a Flag epitope and contained the extracellular, transmem-
brane, and juxtamembrane domains (aa 1–191) of the
human ThRII, but lacked the cytoplasmic kinase domain
for downstream signaling [15]. Overexpressing the DNIIR
transgene has been shown to create a dominant negative
mutation in transgenic mice by competing with the naturally
low levels of endogenous ThRII for TGF-h ligand and by
binding to endogenous TGF-h receptor type I [16]. By
breeding the MT-DNIIR mice with 12T-7f and 12T-10 mice,
we hypothesized that expression of the DNIIR transgene in
the Tag tumors would inhibit TGF-h signaling and alter the
neoplastic phenotype.
Materials and Methods
Generating and Genotyping Transgenic Mice
LPB-Tag transgenic mice lines were generated with the
5V-flanking region of the rat LPB gene ( 10,834 to + 28 bp)
linked to the Tag gene deletion mutant (d1 2005), which
removed expression of the small t antigen [12]. Both 12T-7f
and 12T-10 lines were maintained in the CD1 mouse strain.
MT-DNIIR transgenic mice (MT-DNIIR-27) were generated
using a truncated human ThRII with a Flag epitope as the
DNIIR transgene under the control of the MT promoter [15].
The MT-DNIIR line used in this study was maintained in the
B6D2 mouse strain. 12T-7fTTag+/  females were mated with
MT-DNIIRDNIIR+/ + males to generate 12T-7f/MT-DNIIR and
MT-DNIIR mice in the similar mouse background. The 12T-
7f/MT-DNIIR and MT-DNIIR mice were supplemented with
25mMzinc sulfate in the drinkingwater to enhance transgene
expression. 12T-7fTag+/ females were mated with B6D2F1
males to generate control 12T-7f and nontransgenic (NT)
mice in the same mouse background. Some of the control
12T-7f and NT mice were supplemented with 25 mM zinc
sulfate in the drinking water. 12T-10Tag+/ + females were
mated with MT-DNIIRDNIIR+/ + males to generate 12T-10/
MT-DNIIR mice. To control for genetic background, 12T-
10Tag+/ + femaleswerematedwith B6D2F1males to generate
12T-10 mice. None of the 12T-10/MT-DNIIR or 12T-10
mice were supplemented with 25 mM zinc sulfate in the
drinking water. Mice were genotyped for the DNIIR trans-
gene by polymerase chain reaction (PCR) analysis of
genomic DNA isolated from mouse tails using protei-
nase K digestion and ethanol extraction. The forward ThRII
primer (5V-TCCCACCGCACGTTCAGAAG-3V) and reverse
Flag primer (5V-ATCGTCATCGTCTTTGTAGTC-3V) pro-
duced an amplimer of 506 bp [15]. Mice were genotyped
for the Tag transgene by PCR analysis using the forward
LPB primer (5V-TAGCATCTTGTTCTTAGTCTT-3V) and
reverse Tag pr imer (5 V-CTCCTTTCAAGACCTA-
GAAGGTCCA-3V) to produce an amplimer of 430 bp [12].
Exon 7 of the endogenous mouse casein gene served as an
internal control for the Tag PCR reaction using the forward
casein primer (5V-GATGTGCTCCAGGCTAAAGTT-3V) and
the reverse casein primer (5V-AGAAACGGAATGTTGTG-
GAGT-3V) to generate a 540-bp amplimer [12].
Tissue Preparation and Histopathologic Analysis
Mice were sacrificed by cervical dislocation after the
inhalation of an anesthetic agent according to the policy of
the Vanderbilt University Animal Care Committee. The
prostates were generally dissected into four different lobes
(ventral, lateral, dorsal, and anterior lobes) under a dissect-
ing microscope. When it was not possible to separate the
lateral and dorsal lobes, the tissues were taken together as
the dorsolateral lobe. Seminal vesicle, vas deferens, testis,
periurethral gland, bladder, bulbourethral gland, para-aortic
lymph nodes (LNs), neck LNs, lumbar spine, liver, lung,
kidney, spleen, brain, adrenal, parotid gland, and subman-
dibular gland were also harvested for histologic examina-
tion. Tissues were either frozen on dry ice and stored at
 80jC, or fixed in 10% formalin and processed and
embedded in paraffin using standard techniques. Paraffin-
embedded tissues were cut at 5 Am and sections were used
for H&E staining, immunohistochemistry, and in situ hybrid-
ization. Histology was classified in a blinded manner by two
pathologists (S.B.S. and R.L.R.) based on histopathologic
definitions from the Prostate Pathology Committee of the
National Cancer Institute Mouse Models of Human Cancer
Consortium [17].
Immunohistochemistry
Immunostaining was performed on 5-Am-thick paraffin
sections, which were deparaffinized and rehydrated using
standard techniques [13]. The following primary antibodies
were used (with the indicated dilutions in PBS): (a)SV40 Tag,
Ab-2 (1:100; Oncogene Research Products, Boston, ME); (b)
CG, bovine SP-1 (1:1000; DiaSorin, Stillwater, MN); and
(c) TGF-h1, sc-146 (1:200; Santa Cruz Biotechnology, Santa
Cruz, CA). For Tag-immunostained sections, the same con-
centration of control mouse ascites fluid (Sigma, St. Louis,
MO) was used as a negative control. For CG-immunostained
sections, the same concentration of normal rabbit immuno-
globulin, X903 (Dako, Carpinteria, CA), was used as a
negative control. For TGF-h1–immunostained sections, con-
trol peptide (sc-146P) was added at 10 times the primary
antibody concentration along with the primary antibody as
a negative control, or the same concentration of normal
rabbit immunoglobulin was used as negative control. Color
development was performed with 3,3V-diaminobenzidine
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tetrahydrochloride (Dako). Slides were counterstained with
hematoxylin, dehydrated, and coverslipped. Some of the
immunostaining was quantitated using theMetaMorph image
analysis program.
In Situ Hybridization for DNIIR
In situ hybridization was performed on 5-Am-thick paraf-
fin sections, which were deparaffinized and rehydrated
using standard techniques [15]. Sections were hybridized
to 35S-labeled sense and antisense riboprobes. The MT-
DNIIR plasmid was linearized with EcoRI, and the antisense
probe was made with T7 polymerase. The sense probe was
made from XbaI-linearized plasmid and T3 polymerase.
Slides were exposed to photographic emulsion at 4jC for
1 month and then developed with D19 developer, fixed in
1% acetic acid, and cleared in 30% sodium thiosulfate.
Sections were counterstained with 0.2% toluidine blue.
Kodak Ektachrome film (Eastman Kodak, Rochester, NY)
was used to take photographs under phase contrast, bright
field, and dark field illumination using a microscope (Zeiss,
Thornwood, NY).
Quantitative Real-Time Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR)
RNA was extracted from frozen samples using the
RNeasy Midi Kit 75144 including treatment with DNase
Figure 1. Detection of transgene in transgenic mice. (A) An example of PCR genotyping using primer sets for the Tag transgene. The expected size of the Tag-
amplified product is 430 bp. Transgene was detected in the 12T-7f/MT-DNIIR sample but not in the MT-DNIIR sample. (B) An example of PCR genotyping using
primer sets for the DNIIR transgene. The expected size of the DNIIR-amplified product is 506 bp. Transgene was detected in the 12T-7f/MT-DNIIR sample but not
in the 12T-7f sample.
Figure 2. Illustrations of histopathology of transgenic animals (H&E). (A) NHA in a DLP of a 12-week–old NT mouse. (B) LGPIN (arrow) in a DLP of a 23-week–old
MT-DNIIR mouse. (C) HGPIN (arrow) in a DLP of an 18-week–old 12T-7 mouse. (D) MI (arrow) in a DLP of a 9-month–old 12T-10 mouse. (E) IC (arrow) in a DLP
of a 20-week–old 12T-7f/MT-DNIIR mouse. (F) UC (arrow) in a VP of a 10-month–old 12T-10/MT-DNIIR mouse.
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Table 1. Histopathology of Mice Expressing the Tag Transgene.
Line Mouse number Age AP DLP VP Metastatic site
12T-7f/MT-DNIIR 9237 12 weeks HGPIN HGPIN NHA None
12T-7f/MT-DNIIR 9240 12 weeks HGPIN HGPIN NHA None
12T-7f/MT-DNIIR 9241 12 weeks HGPIN HGPIN NHA None
12T-7f/MT-DNIIR A3474 12 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3476 12 weeks HGPIN HGPIN NHA None
12T-7f/MT-DNIIR A3477 12 weeks HGPIN HGPIN LGPIN None
12T-7f/MT-DNIIR A3478 12 weeks HGPIN HGPIN LGPIN None
12T-7f A3231 12 weeks HGPIN HGPIN LGPIN None
12T-7f A3242 12 weeks HGPIN HGPIN LGPIN None
12T-7f A3246 12 weeks HGPIN HGPIN LGPIN None
12T-7f A3479 12 weeks HGPIN HGPIN HGPIN None
12T-7f A3483 12 weeks HGPIN HGPIN HGPIN None
12T-7f A3484 12 weeks HGPIN HGPIN NHA None
12T-7f/MT-DNIIR 9201 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9207 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9208 16 weeks HGPIN HGPIN, IC HGPIN Lung
12T-7f/MT-DNIIR A3187 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3190 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3199 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3203 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3204 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3207 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3208 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3209 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3499 16 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3505 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3117 16 weeks HGPIN HGPIN NHA None
12T-7f A3120 16 weeks HGPIN HGPIN HGPIN Lung
12T-7f A3218 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3221 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3228 16 weeks HGPIN HGPIN LGPIN None
12T-7f A3232 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3233 16 weeks HGPIN HGPIN LGPIN None
12T-7f A3234 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3235 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3239 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3243 16 weeks HGPIN HGPIN LGPIN None
12T-7f A3244 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3247 16 weeks HGPIN HGPIN LGPIN Lung
12T-7f A3249 16 weeks HGPIN HGPIN LGPIN None
12T-7f A3251 16 weeks HGPIN HGPIN NHA None
12T-7f A3252 16 weeks HGPIN HGPIN HGPIN None
12T-7f A3276 16 weeks HGPIN HGPIN, IC, UC HGPIN, IC, UC LN
12T-7f/MT-DNIIR 9215 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9218 18 weeks HGPIN HGPIN, IC HGPIN Lung, liver, LN, spine
12T-7f/MT-DNIIR 9239 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3028 18 weeks HGPIN HGPIN HGPIN Lung
12T-7f/MT-DNIIR A3078 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3194 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3195 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3490 18 weeks HGPIN HGPIN HGPIN Lung
12T-7f/MT-DNIIR A3491 18 weeks HGPIN HGPIN HGPIN Lung, liver
12T-7f A3104 18 weeks HGPIN HGPIN HGPIN None
12T-7f A3108 18 weeks HGPIN HGPIN HGPIN None
12T-7f A3283 18 weeks HGPIN HGPIN HGPIN None
12T-7f A3285 18 weeks HGPIN, IC HGPIN LGPIN None
12T-7f A3286 18 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9212 20 weeks HGPIN, IC HGPIN HGPIN None
12T-7f/MT-DNIIR 9219 20 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9223 20 weeks HGPIN, IC HGPIN, IC HGPIN None
12T-7f/MT-DNIIR A3087 20 weeks HGPIN HGPIN LGPIN None
12T-7f/MT-DNIIR A3210 20 weeks HGPIN HGPIN, IC LGPIN Lung
12T-7f 9194 20 weeks HGPIN HGPIN HGPIN None
12T-7f 9195 20 weeks HGPIN HGPIN HGPIN None
12T-7f 9197 20 weeks HGPIN HGPIN HGPIN None
12T-7f A3271 20 weeks HGPIN HGPIN HGPIN Lung, liver, spine
12T-7f A3274 20 weeks HGPIN HGPIN HGPIN None
12T-7f A3384 20 weeks HGPIN HGPIN HGPIN None
12T-7f A3387 20 weeks HGPIN HGPIN HGPIN None
12T-7f A3391 20 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9220 23 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR 9227 23 weeks HGPIN HGPIN, IC NHA Lung
270 TGF-B Regulates Prostate Cancer Metastasis Tu et al.
Neoplasia . Vol. 5, No. 3, 2003
79254 (Qiagen, Valencia, CA). RNA concentration was
determined based on absorbance on a spectrophotome-
ter, and RNA quality was assessed by agarose gel
electrophoresis. DNIIR copy numbers were determined
using a Lightcycler fluorescence temperature rapid air
cycler (Roche Molecular Biochemicals, Indianapolis, IN)
with cDNA standard curves and the double-stranded DNA-
binding fluorescent probe SYBR Green. The cDNA tem-
plate was generated from the MT-DNIIR plasmid. The
forward DNIIR primer (5V-AGAAGAATATAACACCAG-
CAATCC-3V) and reverse DNIIR primer (5V-ATC-
CAACGCGGTAGCAGTAGAAGA-3V) generated a 128-bp
amplimer. The specificity of the amplimer in each reaction
was confirmed by the melting curve analysis. Copy num-
bers of mRNA were calculated, using the Lightcycler
software (version 3.5), from serially diluted (1:10) standard
curves (109–103 copies). The serially diluted standards
were simultaneously amplified with the unknown samples
to generate a linear standard curve using the fit points
method of analysis with seven points. Additionally, real-time
RT-PCRwas developed for h-actin as a loading control using
a cDNA template, the forward h-actin primer (5V-ACGGC-
CAGGTCATCACTATTG-3V) and the reverse h-actin primer
(5V-ATGCTACTCAGGCCGGGGA-3V).
Table 1. (continued )
Line Mouse number Age AP DLP VP Metastatic site
12T-7f/MT-DNIIR A3018 23 weeks HGPIN HGPIN LGPIN None
12T-7f/MT-DNIIR A3030 23 weeks HGPIN HGPIN HGPIN None
12T-7f/MT-DNIIR A3081 23 weeks HGPIN HGPIN HGPIN None
12T-7f 9245 23 weeks HGPIN HGPIN HGPIN None
12T-7f 9246 23 weeks HGPIN HGPIN HGPIN None
12T-7f A3258 23 weeks HGPIN HGPIN, IC HGPIN None
12T-7f A3265 23 weeks HGPIN HGPIN LGPIN None
12T-7f A3278 23 weeks HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3130 6 months HGPIN HGPIN HGPIN, MI None
12T-10/MT-DNIIR A3131 6 months HGPIN HGPIN, MI HGPIN None
12T-10/MT-DNIIR A3132 6 months HGPIN HGPIN, MI HGPIN None
12T-10/MT-DNIIR A3133 6 months HGPIN HGPIN HGPIN Lung
12T-10/MT-DNIIR A3134 6 months HGPIN HGPIN, MI HGPIN None
12T-10 A3158 6 months HGPIN HGPIN HGPIN None
12T-10 A3159 6 months HGPIN HGPIN HGPIN None
12T-10 A3160 6 months HGPIN HGPIN HGPIN None
12T-10 A3161 6 months HGPIN HGPIN HGPIN None
12T-10 A3164 6 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3142 7 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3143 7 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3144 7 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3145 7 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3146 7 months HGPIN HGPIN HGPIN None
12T-10 A3162 7 months HGPIN HGPIN, MI HGPIN Lung
12T-10 A3163 7 months HGPIN HGPIN HGPIN None
12T-10 A3169 7 months HGPIN HGPIN, MI HGPIN None
12T-10 A3170 7 months HGPIN HGPIN, MI HGPIN None
12T-10 A3171 7 months HGPIN HGPIN, MI HGPIN Lung
12T-10/MT-DNIIR A3150 8 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3151 8 months HGPIN HGPIN, IC HGPIN None
12T-10/MT-DNIIR A3152 8 months HGPIN HGPIN, MI, IC HGPIN None
12T-10/MT-DNIIR A3407 8 months HGPIN HGPIN, MI HGPIN, MI Lung, liver
12T-10 A3175 8 months HGPIN HGPIN, MI HGPIN None
12T-10 A3176 8 months HGPIN HGPIN, MI HGPIN None
12T-10 A3177 8 months HGPIN HGPIN HGPIN None
12T-10 A3178 8 months HGPIN HGPIN, MI HGPIN None
12T-10 A3179 8 months HGPIN HGPIN HGPIN None
12T-10/MT-DNIIR A3403 9 months HGPIN HGPIN, MI HGPIN None
12T-10/MT-DNIIR A3404 9 months HGPIN HGPIN, MI HGPIN, MI Lung, liver, LN
12T-10/MT-DNIIR A3405 9 months HGPIN HGPIN, MI HGPIN None
12T-10/MT-DNIIR A3406 9 months HGPIN HGPIN, MI HGPIN, MI Lung, liver
12T-10/MT-DNIIR A3408 9 months HGPIN HGPIN, MI HGPIN Lung, liver
12T-10 A3394 9 months HGPIN HGPIN, MI HGPIN None
12T-10 A3395 9 months HGPIN HGPIN, MI HGPIN Lung
12T-10 A3396 9 months HGPIN, MI HGPIN, MI, IC HGPIN Lung, liver
12T-10 A3397 9 months HGPIN HGPIN, MI HGPIN Lung
12T-10/MT-DNIIR A3135 10 months HGPIN, MI HGPIN, MI HGPIN, IC, UC Lung, liver, LN
12T-10/MT-DNIIR A3137 10 months HGPIN HGPIN, IC HGPIN, IC, UC Lung, LN
12T-10/MT-DNIIR A3138 10 months HGPIN, IC HGPIN, MI HGPIN Lung
12T-10 A3168 10 months HGPIN HGPIN, IC HGPIN, MI None
12T-10 A3180 10 months HGPIN HGPIN, MI HGPIN Lung
12T-10 A3184 10 months HGPIN HGPIN, MI HGPIN None
12T-10 A3185 10 months HGPIN HGPIN HGPIN, MI Lung, liver
AP= anterior prostate; VP= ventral prostate.
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Western Blot and Band Quantification
Protein was extracted by sonication and centrifugation of
frozen tissues in RIPA buffer (PBS, pH 7.4, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS) supplemented with 1 mM
PMSF and Complete Mini protease inhibitor cocktail,
1836153 (Roche, Mannheim, Germany). Protein concentra-
tion was determined by the Lowry method using the Bio-Rad
Protein Assay 500-0006 (Bio-Rad Laborator ies,
Hercules, CA). Protein lysates were treated with h-mercap-
toethanol and heated at 70jC for 10 minutes then electro-
phoresed in NuPage 7% Tris –acetate gels EA035A
(Invitrogen, Carlsbad, CA). Proteins were transferred over-
night at 30 V to Invitrolon PVDF membranes LC2005 (Invi-
trogen). Membranes were blocked with blocking buffer
containing 5% skim milk in TBS with 0.1% Tween. For PAI-
I detection, anti–PAI-I polyclonal antibody TP223 (Torrey
Pines Biolaboratories, Houston TX) at 1:1000 dilution in
blocking buffer was used, followed by horseradish perox-
idase–linked antirabbit Ig NA9340 (Amersham Biosciences,
Buckinghamshire, England, UK) at 1:2000 dilution in block-
ing buffer. Bands were visualized using ECL plus RPN2132
(Amersham Biosciences) and Kodak BioMax MR Film 870-
1302 (Eastman Kodak).
For h-actin detection, the PAI-I western membranes were
stripped by incubation in stripping buffer (2% SDS, 62.5 mM
Tris–HCl, pH 7.4, 100 mM h-mercaptoethanol) for 30
minutes at 70jC. Then the membranes were blocked and
probed with monoclonal anti –h-actin antibody A5441
(Sigma) at 1:5000 in blocking buffer, followed by horseradish
peroxidase–linked antimouse Ig NA931V (Amersham Bio-
sciences) at 1:2000 dilution in blocking buffer. Bands were
visualized using ECL plus RPN2132 and Kodak BioMax MR
Film 870-1302.
For band quantitation, the exposed film was scanned to
obtain TIFF images in Adobe Photoshop. With each mem-
brane image, the band intensities in a constant area were
measured using the Scion Image analysis program (Scion,
Frederick, MD). The band intensity values were transferred
to the Microsoft Excel program for statistical analysis.
Statistical Analysis
Heteroskedastic t-test was performed to compare the
Western blot data between two groups. Fisher’s exact test
as well as the Generalized Linear Mode (Logistic Regression
Model) were used to compare the metastasis data between
two groups. P value < .05 was considered statistically sig-
nificant. The analyses were performed in collaboration with
the Vanderbilt Cancer Center Biostatistics Shared Resource.
Results
Generation and Characterization of Transgenic Mice
The 12T-7f line was heterozygous for the Tag transgene,
whereas the 12T-10 line was homozygous for the Tag trans-
gene. The MT-DNIIR line was homozygous for the
DNIIR transgene. Therefore, 12T-7f mice were bred with
MT-DNIIR mice to generate 12T-7f/MT-DNIIR offspring and
MT-DNIIR control offspring. 12T-7f mice were bred with
B6D2F1 mice to generate 12T-7f control offspring and NT
offspring. 12T-10 mice were bred with MT-DNIIR mice to
generate 12T-10/MT-DNIIR mice. 12T-10 mice were bred
with B6D2F1 mice to generate 12T-10 control offspring.
Offspring were genotyped by PCR using genomic DNA
isolated from mouse tail (arrow, Figure 1, A and B).
Histologic examination of the prostates showed progres-
sive tumor development in themice expressing the T antigen,
but minimal or no lesions in the other mice. The prostates
were classified in a blinded manner by two pathologists
(S.B.S. and R.L.R.) as containing no histologic abnormality
(NHA), low-grade prostatic intraepithelial neoplasia (LGPIN),
HGPIN, microinvasive carcinoma (MI), IC, or undifferentiated
carcinoma (UC) [13,17]. Compared to normal areas, LGPIN
andHGPIN were characterized by stratification and crowding
of the epithelial cells within basement membrane-bound
preexisting glands along with cytologic abnormalities such
as nuclear enlargement (arrow, Figure 2, A–C). HGPIN was
distinguished from LGPIN based on the accentuation of
these features including marked nuclear atypia, more hyper-
chromatic nuclei, and higher mitotic and apoptotic rates
(arrow, Figure 2, B and C). MI was recognized as foci of
single cells or groups of cells breaking through the basement
membrane of HGPIN-containing glands into the surrounding
stroma (arrow, Figure 2D). Lesions were designated as IC
when they were more extensive than those described above
as MI, with foci of glands demonstrating invasion (arrow,
Figure 2E ). UC was characterized by invasive lesions that
frequently showed destructive overgrowth of normal prostate
architecture and lacked glandular differentiation but had
cytologic and histologic features typical of neuroendocrine
differentiation (arrow, Figure 2F ). The MT-DNIIR and NT
mice showed predominately NHA or LGPIN and rarely
HGPIN but not cancer in the prostate. Given that carcinoma
was identified only in the mice expressing the T antigen
and predominantly in the dorsolateral lobes, we focused on
the dorsolateral prostate (DLP) in these mice for further
experiments (Table 1).
Both Transgenes and TGF-b1 Were Expressed in Prostate
Lesions
Because human prostate carcinomas arise from the
glandular epithelium, it was important to demonstrate the
presence of both transgenes in the epithelium. Both Tag and
DNIIR transgenes were expressed in luminal epithelial cells
of 12T-7f/MT-DNIIR and 12T-10/MT-DNIIR mice according
to immunohistochemical analyses for Tag (arrow, Figure 3A)
and in situ hybridization analyses for DNIIR (arrow,
Figure 3B). We found stable levels of DNIIR expression
throughout tumor progression as measured by real-time
RT-PCR (Table 2). Additionally, TGF-h1 was identified in
the prostate and localized to the epithelium according to
immunohistochemical analyses (arrow, Figure 3C). The
staining intensities of TGF-h1 were similar based on Meta-
Morph analysis. The presence of TGF-h justified the use of a
dominant negative ThRII to block TGF-h signaling. Thus,
expression of both transgenes and TGF-h1 was seen in the
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prostatic epithelial lesions that developed in the 12T-7f/MT-
DNIIR and 12T-10/MT-DNIIR.
Expression of the DNIIR Transgene Decreased Levels of a
TGF-b Downstream Target, PAI-I
PAI-I expression is positively regulated by TGF-h [9,10].
Using PAI-I as a marker for TGF-h signaling, the presence of
the DNIIR transgene was shown to disrupt TGF-h signaling.
Western blot analyses were performed to determine the PAI-
I and h-actin levels in tissues from age-matched mice. The
PAI-I levels were quantitated using the Scion Image analysis
program and normalized for protein loading by the h-actin
levels. The average normalized level of PAI-I in 12T-7f/MT-
DNIIR mice was significantly lower than the average normal-
ized level of PAI-I in 12T-7f mice (P< .05) (Figure 4, A and
B). Similarly, the average normalized level of PAI-I in 12T-10/
MT-DNIIR mice was significantly lower than the average
normalized level of PAI-I in 12T-10 mice (P< .05) (Figure
4, C and D). Therefore, the DNIIR transgene actively
inhibited TGF-h signaling in the prostate.
12T-7f/MT-DNIIR Mice Tended to Develop More IC But Not
Larger Prostates Compared to 12T-7f Mice
The histologic progression of prostatic neoplasia in
12T-7f/MT-DNIIR (n = 39) mice was similar to that of
12T-7f mice (n=41) from 12 to 23 weeks old. Both lines
predominantly developed HGPIN with glandular proliferation
and hypercellular stroma in the prostate. To determine
whether the loss of TGF-h inhibition in the tumors stimulated
growth, we measured the wet prostatic weights and normal-
ized for differences in animal size by calculating the percent-
age of body weight. Comparing the prostate weights, as
percentage of body weight, of 12T-7f/MT-DNIIR and 12T-7f
mice revealed no increase in tumor size (data not shown).
Invasive periurethral and bulbourethral tumors were rarely
observed in 12T-7f/MT-DNIIR mice (n=2) and 12T-7f mice
(n = 1). Focal lesions of locally invasive carcinoma were
observed more frequently in routine sections of the prostates
of 12T-7f/MT-DNIIR mice (n=6) than in 12T-7f mice (n =3)
(Table 1). None of the control MT-DNIIR mice (n=50) and
NT mice (NT, n = 56) from 12 weeks to 10 months old
developed IC.
12T-7f/MT-DNIIR Mice Tended to Develop Metastasis More
Frequently and Extensively Than 12T-7f Mice
Both 12T-7f/MT-DNIIR and 12T-7f mice developed micro-
scopic neuroendocrine metastases to the para-aortic LNs
(arrow, Figure 5A), lungs (arrow, Figure 5B), liver (Figure
5C), and rarely bones (12T-7f/MT-DNIIR, n=1; 12T-7f, n =1)
(arrow, Figure 5D). Metastases were identified histologically
Table 2. Quantitation of DNIIR Transgene Expression by Real-Time RT-PCR.
Line Mouse number Age Tissue DNIIR level h-Actin level Ratio of DNIIR /h-Actin
12T-7f/MT-DNIIR 9237 12 weeks DLP 3.65E+ 04 1.00E +10 3.7E 06
12T-7f/MT-DNIIR 9241 12 weeks DLP 1.85E+ 05 4.24E +10 4.4E 06
12T-7f/MT-DNIIR 9201 16 weeks DLP 7.65E+ 04 1.19E +10 6.4E 06
12T-7f/MT-DNIIR 9208 16 weeks DLP 1.06E+ 05 1.03E +10 1.0E 05
12T-7f/MT-DNIIR 9218 18 weeks DLP 1.80E+ 04 5.53E +09 3.3E 06
12T-7f/MT-DNIIR A3028 18 weeks DLP 6.02E+ 04 2.60E +10 2.3E 06
12T-7f/MT-DNIIR 9212 20 weeks DLP 4.98E+ 04 4.35E +10 1.1E 06
12T-7f/MT-DNIIR 9223 20 weeks DLP 3.10E+ 04 4.07E +10 7.6E 07
12T-7f/MT-DNIIR 9227 23 weeks DLP 2.40E+ 04 1.07E +10 2.2E 06
12T-7f/MT-DNIIR A3030 23 weeks DLP 5.76E+ 04 1.08E +10 5.3E 06
12T-7f/MT-DNIIR A3407 8 months Liver metastasis 1.69E+ 07 5.89E +10 2.9E 04
12T-7f/MT-DNIIR A3404 9 months Liver metastasis 1.79E+ 03 5.67E +10 3.2E 08
12T-7f/MT-DNIIR A3135 10 months Liver metastasis 1.30E+ 03 6.02E +10 2.2E 08
Levels are listed as copy numbers per 200 ng of total RNA.
Figure 3. Detection of transgene expression in transgenic mice. (A) An example of immunohistochemical analysis shows expression of Tag in an HGPIN lesion
(arrow) in a DLP of a 12T-7f/MT-DNIIR mouse. (B) A light field view of in situ hybridization shows expression of DNIIR in an HGPIN lesion (arrow) in a DLP of a 12T-
7f/MT-DNIIR mouse. (C) An example of immunohistochemical analysis shows localization of TGF-b1 in an HGPIN lesion (arrow) in a DLP of a 12T-7f mouse.
TGF-B Regulates Prostate Cancer Metastasis Tu et al. 273
Neoplasia . Vol. 5, No. 3, 2003
and showed typical features of neuroendocrine differentia-
tion. The metastatic lesions were immunopositive for Tag
(arrow, Figure 5A), TGF-h1 (arrow, Figure 5B), and the
neuroendocrine marker chromogranin A (CG), confirming
their transgene expression and neuroendocrine differentia-
tion (arrow, Figure 5D). More 12T-7f/MT-DNIIR mice (n=7)
developed metastasis than age-matched 12T-7f mice (n=4)
(Table 1). Lung metastasis occurred most commonly
whereas liver metastasis occurred in a subset of those
animals, seemingly indicating more widespread metastasis.
Comparing liver metastasis in the 12T-7f line (n = 1)
(arrow, Figure 5E ) and the 12T-7f/MT-DNIIR line (n = 2)
(arrow, Figure 5F ) showed more extensive metastasis in
the 12T-7f/MT-DNIIR mice. These results in the 12T-7f
Figure 4. Quantitation and normalization of PAI-I levels in transgenic mice. (A) Western blots for PAI-I and for b-actin as a loading control in 12T-7f and 12T-7f/MT-
DNIIR mice. (B) Summary of band intensities from Western blots in (A) along with ratios of PAI-I to b-actin. The average ratio is significantly lower in 12T-7f/MT-
DNIIR mice than in 12T-7f mice ( P < .05). (C) Western blots for PAI-I and for b-actin as a loading control in 12T-10 and 12T-10/MT-DNIIR mice. (B) Summary of
band intensities from Western blots in (C) along with ratios of PAI-I to b-actin. The average ratio is significantly lower in 12T-10/MT-DNIIR mice than in 12T-10 mice
( P < .05).
Figure 5. Metastatic lesions along with immunohistochemical analyses in 12T-7f/MT-DNIIR mice and 12T-7f mice. (A) Tag-expressing metastatic lesion (arrow) in
the para-aortic lymph node of a 12T-7f/MT-DNIIR mouse. (B) TGF-b1–expressing metastatic lesion (arrow) in the lung of a 12T-7 mouse. (C) Metastatic lesion
(arrow) on H&E stain in the liver of a 12T-7 mouse. (D) CG-expressing metastatic lesion (arrow) in the lumbar spine of a 12T-7f mouse. (E) Micrometastases
(arrow) in the liver of a 20-week–old 12T-7f mouse. (F) Extensive micrometastases (arrow) in the liver of an 18-week–old 12T-7f/MT-DNIIR mouse.
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mouse model suggested that loss of the TGF-h pathway in
prostate tumors promotes metastatic disease.
12T-10/MT-DNIIR Mice Tended to Develop More IC But Not
Larger Prostates Compared to 12T-10 Mice
Characterizing the effects ofDNIIR overexpression on the
tumors in the 12T-10 line showed an even more pronounced
effect on tumor progression. The histologic progression of
the primary prostatic neoplasia in 12T-10/MT-DNIIR mice
was similar to that of 12T-10 mice. The 12T-10/MT-DNIIR
mice (n=22) and 12T-10 mice (n=23) from 6 to 10 months
old progressively developed HGPIN, locally invasive neuro-
endocrine carcinoma in the prostate, and neuroendocrine
metastasis. Comparing the prostate weights, as percent of
body weight, of 12T-10/MT-DNIIR and 12-T10 mice showed
no increase in tumor size (data not shown). Invasive peri-
urethral and bulbourethral tumors were rarely observed in
12T-10/MT-DNIIR (n=3) and 12T-10 (n =1) mice. The inci-
dence of IC was higher in the 12T-10/MT-DNIIR mice (n =5)
than 12T-10 mice (n=2) (Table 1).
12T-10/MT-DNIIR Mice Developed Significantly More
Extensive Metastasis Than 12T-10 Mice
The 12T-10/MT-DNIIR and 12T-10 mice developed LN,
lung, and liver metastases similar to, but more frequently
than, 12T-7f/MT-DNIIR and 12T-7f mice. According to immu-
nohistochemical and real-time RT-PCR analyses, the meta-
static lesions expressed Tag, TGF-h1, CG, and DNIIR
(Table 2). Based on histologic examination, the cumulative
incidence of metastasis was not different between the 12T-
10/MT-DNIIR (n = 8) and 12T-10 (n = 7) mice (Table 1).
However, the extent of metastatic disease was prominently
Figure 6. Comparison of metastasis in 12T-10/MT-DNIIR mice and 12T-10 mice. (A and B) Gross metastatic lesions (arrow) in the liver of a 12T-10/MT-DNIIR
mouse and accompanying histology. (C and D) No gross lesions in the liver of an age-matched 12T-10 mouse and accompanying histology. (E) Comparison of
incidence (%) of gross metastasis over time in 12T-10/MT-DNIIR (., n = 22) mice versus 12T-10 (n, n = 23) mice. The incidence ratio of metastasis is significantly
greater in 12T-10/MT-DNIIR mice than in 12T-10 mice ( P < .05).
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increased in the 12T-10/MT-DNIIRmice compared to 12T-10
mice. Grossly evident metastatic nodules in the liver and
lungs from 12T-10/MT-DNIIRmice (arrow, Figure 6, A and B)
were noted but no grossly evident metastases were
observed in those organs from age-matched 12T-10 mice
(Figure 6, C and D). Comparing the cumulative incidence of
gross metastasis over time between 12T-10/MT-DNIIR mice
(., n=6/22) and 12T-10 (n, n=1/23) mice showed a statisti-
cally significant (P < .05) increase in the 12T-10/MT-DNIIR
mice (Figure 6E). Furthermore, comparing only mice with
metastasis showed a statistically significant (P < .05)
increase in gross metastasis in 12T-10/MT-DNIIR mice
(n =6/8) compared with 12T-10 mice (n=1/7). These results
in the 12T-10 mousemodel demonstrated that a loss of TGF-
h signaling in metastatic prostate cancer increases the
amount of metastatic lesions.
Discussion
In summary, this study has demonstrated that disruption of
TGF-h signaling modulates progression in late-stage pros-
tate cancer, specifically metastasis. Although more IC foci
were noted in routine sections in the mice expressing the
DNIIR and Tag transgenes, the increases were not statisti-
cally significant (Table 3). Therefore, the effect onmetastasis
was not simply due to the development of more IC. Instead,
the effect must have been either on the development of
metastasis and/or growth at the metastatic site. Because the
MT promoter is not prostate-specific, more direct effects on
the immune system or angiogenesis cannot be ruled out.
Nevertheless, the DNIIR transgene had a direct effect of
disrupting the TGF-h pathway in the prostate tumors as
demonstrated by the significant reduction in levels of PAI-I.
Decreased levels of PAI-I, an inhibitor of urokinase-type
plasminogen activator (uPA) that mediates extracellular
matrix proteolysis, may be a possible mechanism for the
increased metastasis in our model because it has been
demonstrated that PAI-I is present at low levels in several
human prostate cancer cell lines including PC-3 cells and
increasing PAI levels by stable transfection decreases meta-
stasis of PC-3 cells in mice [18,19]. Other intracellular
effectors of TGF-h might also be causally involved in induc-
tion of prostate cancer metastasis. It has been reported in
breast and colon cancers that TGF-h signaling initially has a
negative effect but eventually exerts a positive effect
on tumor progression. For example, blocking TGF-h is
important for tumor growth, but subsequent restoration of
the TGF-h pathway contributes to tumor cell motility, epi-
thelial-to-mesenchymal transition, and ultimately metastasis
[20,21]. Those reports focused on nonprostatic cancer and
used different systems such as injection of cell lines into mice
for tumor and metastasis formation.
In human prostate cancer, the loss of the ThRII occurs
most commonly in advanced stage disease [4,5], suggesting
that this pathway does not function as a positive influence on
the spread of this disease. These studies correlated a
dysfunctional TGF-h receptor pathway with tumor grade at
the primary site but did not prove that the loss of the receptor
was responsible for cancer progression. Our study in two
transgenic animal models provides proof, rather than a
pathologic correlation, that disruption of TGF-h regulation
is important for increasing metastatic burden. This is espe-
cially critical in human prostate cancer that metastasizes in
end-stage disease mainly to the bone, where high TGF-h
levels are naturally found [22]. Metastatic initiation and
growth will be important targets for future study and possibly
therapy because limiting metastasis would allow for more
successful treatment of prostate cancer [1]. The majority of
human prostate cancer metastases are moderate to poorly
differentiated adenocarcinomas, but these mouse models,
similar to other SV40 T antigen models, develop invasive and
metastatic poorly differentiated carcinomas with neuroendo-
crine differentiation [17]. Murine trangenic models to study
human prostate cancer have some limitations because mice
do not naturally develop prostate cancer and results in mice
do not always translate directly to humans. Nevertheless, a
recent report has identified the neuroendocrine phenotype
and TGF-h pathway as important prognostic factors in
human prostate cancer [23]. Although TGF-h loss has been
associated with human prostate cancer progression, it has
not been determined whether that loss was a cause or
consequence of tumor progression. Our animal models of
prostate cancer demonstrate genetic and histopathologic
changes analogous to those in human prostate cancer.
Our data in these models suggest for the first time that there
is a clinically relevant selective advantage for loss of TGF-h
regulation as a cause of increased metastatic burden. We
hope to use thesemodels to identify novel TGF-h targets that
would be tested in human samples.
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